Latest News

  • PARIS, France and CAMBRIDGE, MA, USA  – Sanofi and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for the treatment of rare genetic diseases. Specifically: Sanofi will obtain global development and commercialization rights...
  • VANCOUVER, British Columbia – Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, provided key accomplishments from the past year and announced priorities for 2018. “2017 was a great year for Zymeworks and we are poised to achieve a number of important corporate milestones in 2018,” said Ali Tehrani,...
  • Alzheimer’s disease is a devastating brain illness that affects an estimated 47 million people worldwide. It is the most common cause of dementia in the Western world. Despite this, there are currently no treatments that are effective in curing Alzheimer’s disease or preventing its relentless progression. Alzheimer’s disease is caused...

Videos

Rare disease spotlight

Twitter

He’s been working so hard to be able to swim across the deep-end for three years. He never gives up. This year, he’s done it 🙌 #SeeTheAbility

Late this afternoon, the FDA approved Fintepla for use in Dravet syndrome! Congratulations to @zogenix and thank you to all of our families who participated in the trials and helped bring this to fruition.
https://www.prnewswire.com/news-releases/fda-approves-new-therapy-for-dravet-syndrome-301084154.html

Congolese diplomat, Raymond Serge Bale, shared one of the intentions of the resolution that established World Sickle Cell Day was to help end the long isolation of #sicklecell disease.

#WorldSickleCellDay #sicklecell101 #WSCD20

Load More...